PND21 COST-EFFECTIVENESS OF RASAGILINE COMPARED TO OTHER FIRST LINE TREATMENT OPTIONS OF EARLY PARKINSONS DISEASE IN THE UNITED STATES
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74815-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)74815-4/fulltext
Title :
PND21 COST-EFFECTIVENESS OF RASAGILINE COMPARED TO OTHER FIRST LINE TREATMENT OPTIONS OF EARLY PARKINSONS DISEASE IN THE UNITED STATES
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74815-4&doi=10.1016/S1098-3015(10)74815-4
First page :
Section Title :
Open access? :
No
Section Order :
741